CardioComm Solutions Appoints New CFO
CardioComm Solutions Appoints New CFO
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce the appointment of Mr. Robert Caines as Chief Financial Officer ("CFO") of the Company.
多伦多,安大略省--(Newsfile Corp. -2024年1月9日)-CardioComm Solutions, Inc. (tsxv: EKG) (“CardioComm”), 是一家提供全球货币消费性心脏监测和医疗心电图(“ECG”)软件解决方案的公司，欣然宣布将与公司的某些债权人进入债务清算协议，根据该协议，公司将以0.01美元的平均价格发行累计41834010股公司的普通股(“股份”)给债权人，以清偿公司拖欠的累计418340.10美元的债务。待发行的股票将依据适用证券法和tsx Venture Exchange的政策，受到持有期为四个月的限制。债务清算交易和其下发行的股份需要获得tsx Venture Exchange的批准。CardioComm"或"公司全球医疗消费级心脏监测和心电图(ECG)软件解决方案提供商"的先生代表欣然宣布任命罗伯特•凯恩斯先生为公司的首席财务官(CFO)。
Effective January 8, 2024, Mr. Caines assumed the role of CFO, replacing Mr. Etienne Grima who served as interim CFO since August 3, 2023. Mr. Caines will also continue to serve as Chairman of the Board of Directors and Mr. Grima will continue to serve as the Company's Chief Executive Officer.
从2024年1月8日起，凯恩斯先生将担任CFO一职，取代自2023年8月3日以来担任临时CFO的埃蒂安·格里马先生。凯恩斯先生还将继续担任董事会主席，格里马先生将继续担任公司的首席执行官。
The Company also announces that it has issued 250,000 stock options to Etienne Grima, the Company's CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per share for five years from the date of grant and vest immediately. The grant is subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
公司还宣布，根据其就业协议，向公司CEO埃蒂安•格里马授予了250,000股期权。期权行使价格为每股0.05美元，有效期为授予之日起五年，立即生效。该授予受公司期权计划的规定，TSX创业公司的政策以及适用的证券法律的约束。
To learn more about CardioComm's products and for further updates please visit the Company's websites at and .
欲了解更多CardioComm产品信息和更新，请访问公司网站、、。
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
关于CardioComm Solutions
CardioComm Solution公司拥有专利和专有技术，用于记录、查看、分析和存储心电图以诊断和治疗心脏患者。产品通过一个外部分销网络和一个北美销售团队的组合在全球销售。CardioComm Solution公司获得了ISO 13485和ISO 27001认证，符合HIPAA标准，并持有美国(FDA)和加拿大(加拿大卫生部)的医疗器械许可和销售许可证。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
欲了解更多信息请联系：
Etienne Grima，首席执行官
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
前瞻性声明
本新闻稿中包括的关于未来表现和结果、预期、规划、策略、重点、承诺和其他声明（包括与我们社会、环境和其他可持续性目标有关的声明）的非历史事实的前瞻性声明，是根据美国联邦证券法的定义而作出的前瞻性声明。本新闻稿中关于我们环境和其他可持续性计划和目标的前瞻性声明以及其他声明并不意味着这些声明对于投资者、我们的业务、运营结果、财务状况、前景或策略、对我们在可持续发展事项上的影响或其他当事方来说均是重要的，或者必须披露在我们向证券交易委员会（“SEC”）或其他监管机构的备案中。此外，历史、现有及未来涉及社会、环境和可持续性的相关声明可能是基于仍在发展的衡量进展的标准、不断演变的内部控制和流程以及假设，在将来可能会发生变化。前瞻性声明基于当前的信仰、期望和假设，并受到可能导致实际结果与前瞻性声明有实质性差异的重大风险、不确定性和情况变化的影响。
本发布可能包含某些前瞻性声明和与CardioComm Solutions的财务状况、经营业绩和业务有关的某些前瞻性信息以及CardioComm Solutions关于这些项目的某些计划和目标。这些声明和信息反映了管理层的目前信仰，并基于目前可供管理层使用的信息。nature，forward-looking statements and forward-looking information involve risk and uncertainty因为forward-looking statements和forward-looking information涉及到将来会发生的事件和情况,并且有很多因素可能会使实际结果和发展与这些forward-looking statements和forward-looking information所表达或暗示的结果和发展有所不同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在评估这些声明时，读者不应过多依赖前瞻性声明和前瞻性信息。除适用法律要求，包括但不限于51-102国家法令第5.8(2)条款，本公司将不承担更新在本次发布中包含的前瞻性声明和前瞻性信息的责任，而其他的行为须履行适用法律要求。持续披露义务).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX Venture Exchange及其监管服务提供者（如TSX Venture Exchange的政策中所定义的那样）均不对本发布的充分性或准确性承担责任。
To view the source version of this press release, please visit
要查看此新闻发布的源版本，请访问